

1/16 1626

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Congxin Liang

Title: ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS

Docket No.: 1361.124US1
Filed: April 12, 2007
Examiner: Golam Shameem
Customer No.: 21186

Serial No.: 10/580,670
Due Date: N/A
Group Art Unit: 1626
Confirmation No.: 5025

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

- Return Postcard
 Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (2 pgs.) Copies of Cited References (21).

If not provided for in a separate paper filed herewith, please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
Customer No.: 21186

By: 
Albin J. Nelson
Reg. No. 28,650

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 6th day of March, 2009.

James Kanyusik
Name


Signature



S/N 10/580,670

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Congxin Liang	Examiner:	Golam Shameem
Serial No.:	10/580,670	Group Art Unit:	1626
Filed:	April 12, 2007	Docket:	1361.124US1
Customer No.:	21186	Confirmation No.:	5025
Title:	ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS		


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached PTO 1449 Form be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the PTO 1449 Form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

Pursuant to 37 C.F.R. § 1.98(a)(2), copies of cited U.S. Patents and Published Applications, and Non-Published Applications identifiable by USPTO Serial Number, are no longer required to be provided to the Office. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. § 1.98(a)(2).



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
Serial Number: 10/580,670
Filing Date: April 12, 2007
Title: ADVANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS

Page 2
Dkt: 1361.124US1

The Examiner is invited to contact the Applicant's Representative at the telephone number indicated if there are any questions regarding this communication.

Respectfully submitted,

SCHWEGMAN, LUNDBERG & WOESSNER, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6939

Date March 4, 2009 By Albin J. Nelson
AJN: jek Reg. No. 28,650

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 654 day of March, 2009.

James Kanyusik
Name


Signature